Search Results

Massive Bio, a leader in AI-powered cancer clinical trial enrollment, announced a strategic partnership with Perthera.ai, a pioneer in connecting oncologists and patients with biomarker-based therapy options.

Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”) , a precision oncology molecular profiling company with a novel phosphoprotein-based laboratory developed test (LDT), today announced its partnership with Perthera , a market leader in Precision Oncology technology and services. The alliance will facilitate and accele

Pancreatic Cancer Action Network and Perthera Study in Lancet Oncology Underscores the Urgent Need for Every Pancreatic Cancer Patient to Get Tested Through a Molecular Profiling Platform